Home » Topics » Regulatory » EMA

EMA
RSS

CHMP recommends new label update for GSK's Pandemrix

July 26, 2011

EMA recommends orphan drug status for 4SC's resminostat

July 26, 2011

CHMP issues opinion on Zytiga in prostate cancer

July 25, 2011

Afinitor recommended for new European approval

July 25, 2011

Tarceva recommended for E.U. approval as first-line therapy in distinct type of lung cancer

July 25, 2011

CHMP makes recommendations following review of pioglitazone-containing medicines

July 25, 2011

Positive CHMP opinion for Incivo

July 25, 2011

EMA's CHMP recommends approval of dexdor

July 25, 2011

EMA accepts Santhera Pharmaceuticals' idebenone MAA for review

July 22, 2011

Pfizer withdraws application to extend Macugen indication in E.U.

July 20, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 15, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...